Podcast appearances and mentions of Anita H Clayton

Join Dr. Andy Cutler as he speaks with Dr. Anita Clayton about one of the most common yet least discussed side effects of psychotropic medications—sexual dysfunction. They explore the different aspects of sexual dysfunction that may arise as a side effect, how to distinguish these from symptoms of psychiatric or medical disorders, and how to collaborate with patients to effectively address this challenging issue.  Anita H. Clayton, MD, Wilford W. Spradlin Professor and Chair of Psychiatry & Neurobehavioral Sciences, and Professor of Clinical Obstetrics & Gynecology at the University of Virginia School of Medicine, has focused her research on major depressive disorder, mood disorders associated with reproductive-life events in women (reproductive psychiatry), sexual dysfunction related to illness and medications, and the assessment and treatment of primary sexual disorders.    Andrew J. Cutler, MD is a distinguished psychiatrist and researcher with extensive experience in clinical trials and psychopharmacology. He currently serves as the Chief Medical Officer of Neuroscience Education Institute and holds the position of Clinical Associate Professor of Psychiatry at SUNY Upstate Medical University in Syracuse, New York.    Resources  Changes in Sexual Functioning Questionnaire short- form (CSFQ-14)  Validation study for CSFQ-14   

Go online to PeerView.com/AFZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in psychiatry discuss recent advances in the management of patients with major depressive disorder and postpartum depression. Upon completion of this activity, participants should be better able to: Recognize the burden of major depressive disorder and postpartum depression and the impact of delayed or suboptimal treatment on patient outcomes, Describe the role of GABAergic dysregulation in the pathophysiology of depression and the rationale for GABA-A receptor modulation with neuroactive steroids, Evaluate the mechanisms of action, efficacy, safety, and tolerability of current and emerging treatments for major depressive disorder and postpartum depression, recognizing potential implications for the future treatment landscape, Implement evidence-based, individualized treatment plans for patients with major depressive disorder and postpartum depression.

Go online to PeerView.com/AFZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in psychiatry discuss recent advances in the management of patients with major depressive disorder and postpartum depression. Upon completion of this activity, participants should be better able to: Recognize the burden of major depressive disorder and postpartum depression and the impact of delayed or suboptimal treatment on patient outcomes, Describe the role of GABAergic dysregulation in the pathophysiology of depression and the rationale for GABA-A receptor modulation with neuroactive steroids, Evaluate the mechanisms of action, efficacy, safety, and tolerability of current and emerging treatments for major depressive disorder and postpartum depression, recognizing potential implications for the future treatment landscape, Implement evidence-based, individualized treatment plans for patients with major depressive disorder and postpartum depression.

Go online to PeerView.com/AFZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in psychiatry discuss recent advances in the management of patients with major depressive disorder and postpartum depression. Upon completion of this activity, participants should be better able to: Recognize the burden of major depressive disorder and postpartum depression and the impact of delayed or suboptimal treatment on patient outcomes, Describe the role of GABAergic dysregulation in the pathophysiology of depression and the rationale for GABA-A receptor modulation with neuroactive steroids, Evaluate the mechanisms of action, efficacy, safety, and tolerability of current and emerging treatments for major depressive disorder and postpartum depression, recognizing potential implications for the future treatment landscape, Implement evidence-based, individualized treatment plans for patients with major depressive disorder and postpartum depression.

Go online to PeerView.com/AFZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in psychiatry discuss recent advances in the management of patients with major depressive disorder and postpartum depression. Upon completion of this activity, participants should be better able to: Recognize the burden of major depressive disorder and postpartum depression and the impact of delayed or suboptimal treatment on patient outcomes, Describe the role of GABAergic dysregulation in the pathophysiology of depression and the rationale for GABA-A receptor modulation with neuroactive steroids, Evaluate the mechanisms of action, efficacy, safety, and tolerability of current and emerging treatments for major depressive disorder and postpartum depression, recognizing potential implications for the future treatment landscape, Implement evidence-based, individualized treatment plans for patients with major depressive disorder and postpartum depression.

Go online to PeerView.com/AFZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in psychiatry discuss recent advances in the management of patients with major depressive disorder and postpartum depression. Upon completion of this activity, participants should be better able to: Recognize the burden of major depressive disorder and postpartum depression and the impact of delayed or suboptimal treatment on patient outcomes, Describe the role of GABAergic dysregulation in the pathophysiology of depression and the rationale for GABA-A receptor modulation with neuroactive steroids, Evaluate the mechanisms of action, efficacy, safety, and tolerability of current and emerging treatments for major depressive disorder and postpartum depression, recognizing potential implications for the future treatment landscape, Implement evidence-based, individualized treatment plans for patients with major depressive disorder and postpartum depression.

Go online to PeerView.com/AFZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in psychiatry discuss recent advances in the management of patients with major depressive disorder and postpartum depression. Upon completion of this activity, participants should be better able to: Recognize the burden of major depressive disorder and postpartum depression and the impact of delayed or suboptimal treatment on patient outcomes, Describe the role of GABAergic dysregulation in the pathophysiology of depression and the rationale for GABA-A receptor modulation with neuroactive steroids, Evaluate the mechanisms of action, efficacy, safety, and tolerability of current and emerging treatments for major depressive disorder and postpartum depression, recognizing potential implications for the future treatment landscape, Implement evidence-based, individualized treatment plans for patients with major depressive disorder and postpartum depression.

Go online to PeerView.com/TTU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in psychiatry discusses the evidence for the use of GABA-modulating neuroactive steroids for major depressive disorder. Upon completion of this CE activity, participants will be able to: Summarize the evidence supporting a role for GABAergic dysfunction and altered neuroactive steroid signaling in major depressive disorder (MDD), Recognize the burden of MDD and the impact of delayed or suboptimal treatment on patient outcomes, Evaluate recent safety and efficacy data related to emerging treatment options for MDD, recognizing potential implications for the future treatment landscape.

Go online to PeerView.com/TTU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in psychiatry discusses the evidence for the use of GABA-modulating neuroactive steroids for major depressive disorder. Upon completion of this CE activity, participants will be able to: Summarize the evidence supporting a role for GABAergic dysfunction and altered neuroactive steroid signaling in major depressive disorder (MDD), Recognize the burden of MDD and the impact of delayed or suboptimal treatment on patient outcomes, Evaluate recent safety and efficacy data related to emerging treatment options for MDD, recognizing potential implications for the future treatment landscape.

Go online to PeerView.com/TTU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in psychiatry discusses the evidence for the use of GABA-modulating neuroactive steroids for major depressive disorder. Upon completion of this CE activity, participants will be able to: Summarize the evidence supporting a role for GABAergic dysfunction and altered neuroactive steroid signaling in major depressive disorder (MDD), Recognize the burden of MDD and the impact of delayed or suboptimal treatment on patient outcomes, Evaluate recent safety and efficacy data related to emerging treatment options for MDD, recognizing potential implications for the future treatment landscape.

Go online to PeerView.com/TTU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in psychiatry discusses the evidence for the use of GABA-modulating neuroactive steroids for major depressive disorder. Upon completion of this CE activity, participants will be able to: Summarize the evidence supporting a role for GABAergic dysfunction and altered neuroactive steroid signaling in major depressive disorder (MDD), Recognize the burden of MDD and the impact of delayed or suboptimal treatment on patient outcomes, Evaluate recent safety and efficacy data related to emerging treatment options for MDD, recognizing potential implications for the future treatment landscape.

Go online to PeerView.com/TTU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in psychiatry discusses the evidence for the use of GABA-modulating neuroactive steroids for major depressive disorder. Upon completion of this CE activity, participants will be able to: Summarize the evidence supporting a role for GABAergic dysfunction and altered neuroactive steroid signaling in major depressive disorder (MDD), Recognize the burden of MDD and the impact of delayed or suboptimal treatment on patient outcomes, Evaluate recent safety and efficacy data related to emerging treatment options for MDD, recognizing potential implications for the future treatment landscape.

Go online to PeerView.com/TTU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in psychiatry discusses the evidence for the use of GABA-modulating neuroactive steroids for major depressive disorder. Upon completion of this CE activity, participants will be able to: Summarize the evidence supporting a role for GABAergic dysfunction and altered neuroactive steroid signaling in major depressive disorder (MDD), Recognize the burden of MDD and the impact of delayed or suboptimal treatment on patient outcomes, Evaluate recent safety and efficacy data related to emerging treatment options for MDD, recognizing potential implications for the future treatment landscape.

Go online to PeerView.com/TTU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in psychiatry discusses the evidence for the use of GABA-modulating neuroactive steroids for major depressive disorder. Upon completion of this CE activity, participants will be able to: Summarize the evidence supporting a role for GABAergic dysfunction and altered neuroactive steroid signaling in major depressive disorder (MDD), Recognize the burden of MDD and the impact of delayed or suboptimal treatment on patient outcomes, Evaluate recent safety and efficacy data related to emerging treatment options for MDD, recognizing potential implications for the future treatment landscape.

Go online to PeerView.com/TTU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in psychiatry discusses the evidence for the use of GABA-modulating neuroactive steroids for major depressive disorder. Upon completion of this CE activity, participants will be able to: Summarize the evidence supporting a role for GABAergic dysfunction and altered neuroactive steroid signaling in major depressive disorder (MDD), Recognize the burden of MDD and the impact of delayed or suboptimal treatment on patient outcomes, Evaluate recent safety and efficacy data related to emerging treatment options for MDD, recognizing potential implications for the future treatment landscape.

Host: Anita H. Clayton, MD Listen in as Dr. Anita Clayton takes us through the importance of screening for postpartum depression (PPD) and reaching an early diagnosis in the perinatal and postnatal stages of pregnancy. This Women's Health 2021 lecture also covers the exciting new agents that are targeted specifically for PPD. Find out how they compare to the traditional antidepressants and how they can improve the quality of life for your patients with PPD.

May is Maternal Mental Health Month, and moms around the world could probably use a break. During the COVID-19 pandemic, they have done even more of the childcare and housework, while also, in many cases, keeping up with their careers. How has the pandemic affected their mental health—either by creating new problems or by exacerbating perennial concerns?    In this edition of Psych Pearls, Anita H. Clayton, MD, explores the wide and varied field of maternal mental health. Along with the effects of the pandemic, Clayton discusses pre-natal mental health care, new and emerging treatments for postpartum depression and psychosis, and how what she saw in a courtroom set her on a path to becoming a renowned expert on maternal wellness.     Dr Clayton is the David C. Wilson Professor and chair of the Department of Psychiatry and Neurobehavioral Sciences at the University of Virginia, with a secondary appointment as professor of clinical obstetrics and gynecology. She is the author of Satisfaction: Women, Sex, and the Quest for Intimacy, published by Ballantine Books in 2007, and an editor of the 2005 Women’s Mental Health: A Comprehensive Textbook. She is also a program co-chair of the Annual Psychiatric TimesTM World CME Conference.   

Why are so many women dissatisfied with their sex lives? Something is missing from their intimate encounters ...Their relationships are suffering. Many women find themselves wondering what’s wrong with them. If you’re a woman and any of this sounds familiar, Dr. Anita H. Clayton wants you to know that there’s nothing wrong with you–what’s wrong is the ridiculous fantasies you’ve been sold about sex, and the unrealistic expectations you cling to.  

Is something missing from your intimate encounters?  Are you not interested in sex anymore, or interested but can’t get aroused? Maybe you get aroused but have neither the desire nor the energy to follow through. You find yourself wondering what’s wrong with you. Dr. Anita H. Clayton wants you to know that there’s nothing wrong with you–what’s wrong is the ridiculous fantasies you’ve been sold about sex, and the unrealistic expectations you cling to

Why are so many women dissatisfied with their sex lives? Something is missing from their intimate encounters ...  Their relationships are suffering. Many women find themselves wondering what’s wrong with them. If you’re a woman and any of this sounds familiar, Dr. Anita H. Clayton wants you to know that there’s nothing wrong with you–what’s wrong is the ridiculous fantasies you’ve been sold about sex, and the unrealistic expectations you cling to.